[Myopathy and osteomalacia after longterm antiepileptic treatment (author's transl)].
D000293:Adolescent; D000328:Adult; D000469:Alkaline Phosphatase / Q000097:blood; D000927:Anticonvulsants / Q000009:adverse effects*; D002118:Calcium / Q000097:blood; D002128:Calcium Metabolism Disorders / Q000139:chemically induced / Q000188:drug therapy; D002648:Child; D004827:Epilepsy / Q000188:drug therapy*; D005260:Female; D006801:Humans; D008134:Long-Term Care; D009133:Muscular Atrophy / Q000139:chemically induced; D009135:Muscular Diseases / Q000139:chemically induced*; D010018:Osteomalacia / Q000139:chemically induced*; D010672:Phenytoin / Q000009:adverse effects*; D010758:Phosphorus / Q000097:blood; D010760:Phosphorus Metabolism Disorders / Q000139:chemically induced / Q000188:drug therapy; D012279:Rickets / Q000139:chemically induced; D014807:Vitamin D / Q000627:therapeutic use
D000927:Anticonvulsants; D014807:Vitamin D; D010758:Phosphorus; D010672:Phenytoin; D000469:Alkaline Phosphatase; D002118:Calcium
Myopathie und Osteomalazie nach langdauernder antiepileptischer Behandlung